Compare · NVO vs PAHC
NVO vs PAHC
Side-by-side comparison of Novo Nordisk A/S (NVO) and Phibro Animal Health Corporation (PAHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PAHC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 147.8x PAHC ($1.46B).
- PAHC has been more active in the news (16 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for PAHC).
- Company
- Novo Nordisk A/S
- Phibro Animal Health Corporation
- Price
- -
- -
- Market cap
- $215.46B
- $1.46B
- 1M return
- -
- -0.43%
- 1Y return
- -
- +10.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 9
- 16
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Phibro Animal Health Corporation
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PAHC
- Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
- VP Finance and Treasurer Rodriguez Patrick was granted 1,503 shares (SEC Form 4)
- Chief Financial Officer David Glenn was granted 3,334 shares, increasing direct ownership by 6% to 54,811 units (SEC Form 4)
- Chief Operating Officer Miller Larry Lee was granted 3,522 shares, increasing direct ownership by 10% to 38,071 units (SEC Form 4)
- Director Bendheim Jonathan was granted 2,716 shares, increasing direct ownership by 83% to 5,984 units (SEC Form 4)
- Officer Weinstein Judith was granted 2,478 shares, increasing direct ownership by 83% to 5,453 units (SEC Form 4)
- Executive Chairman Bendheim Jack was granted 12,103 shares (SEC Form 4)
- President and CEO Bendheim Daniel M was granted 11,699 shares, increasing direct ownership by 336% to 15,177 units (SEC Form 4)
- Officer Escudero Lisa Ann was granted 1,547 shares, increasing direct ownership by 82% to 3,434 units (SEC Form 4)
- Executive Chairman Bendheim Jack disposed of $84,287 worth of shares (2,303 units at $36.60) (SEC Form 4) to cover withholding tax